Navigation Links
New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer
Date:9/22/2009

KVISTGAARD, Denmark, September 22 /PRNewswire-FirstCall/ -- Bavarian Nordic A/S (OMX: BAVA) yesterday presented further detailed PROSTVAC(TM) data at the European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO Congress in Berlin, Germany.

Further data from a Phase II double-blind, prospective randomized placebo-controlled study of 125 patients with metastatic prostate cancer was presented by Dr. Wayne Godfrey, Senior Medical Director, BN ImmunoTherapeutics.

The headline data as previously reported showed that patients in the PROSTVAC(TM) group had a significantly longer median overall survival by 8.5 months compared to the control group. The hazard ratio estimate for overall survival from the study is 0.56 (95% CI 0.37-0.85). The statistical significance in the final data set is (p=0.006). PROSTVAC(TM) also demonstrated a very favourable safety and tolerability profile.

A new statistical analysis of the data set showed that patients receiving PROSTVAC(TM) benefitted from the treatment regardless of their general condition or their median predicted survival, determined by the Halabi score. Similarly, when grouped by a number of relevant parameters, e.g. PSA level, PROSTVAC(TM) patients benefitted from treatment as compared to the control group. This data indicates that PROSTVAC(TM) is universally applicable to a wide range of prostate cancer patients. This confirms PROSTVAC(TM)'s potential to address a significant medical need and market opportunity. Furthermore, it will be useful in further defining the patient population for the pivotal phase III program.

An abstract from Dr. Godfrey's presentation is now available online at http://ex2.excerptamedica.com/CIW-09ecco/

Abstract no. O-7002.

Title: "Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)"

As part of Bavarian Nordic's continued communication strategy on PROSTVAC(TM), the company will participate in the 16th Annual Prostate Cancer Foundation Scientific Retreat on September 24-26 at Lake Tahoe, Nevada, where a PROSTVAC(TM) poster has been accepted for presentation.

Anders Hedegaard, President & CEO of Bavarian Nordic said: "As we continue to analyse our PROSTVAC(TM) data, we gain new insight in the positive features of the vaccine and important information to facilitate the future clinical development of PROSTVAC(TM). With today's presentation at the ECCO congress along with our recent presentation at ASCO and other cancer congresses, we continue to broaden the awareness of PROSTVAC(TM) among leading cancer experts."

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

About Bavarian Nordic

Bavarian Nordic A/S is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's pipeline is focused in the three areas; biodefence, cancer and infectious diseases, and includes seven development programmes. Two programmes are ready for Phase III: IMVAMUNE(R), a third-generation smallpox vaccine is being developed under a contract with the US government, and PROSTVAC(TM), a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit http://www.bavarian-nordic.com


'/>"/>
SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)
2. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
3. New Independent Research Study Indicates That Cylexs ImmuKnow Test May Identify Kidney Transplant Patients at Risk for Early Acute Rejection
4. Vaccines are Likely to Cause Insulin Dependent Diabetes in Over 2% of Children With a Strong Family History of Insulin Dependent Diabetes, New Data Indicates
5. Principle of Recursive Genome Function Supersedes Dogmas; By Andras Pellionisz, Online Ahead of Print; (Scientific Visionary Vindicated)
6. U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis
7. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. New study indicates smallpox vaccination effective for decades
10. New study indicates smallpox vaccination effective for decades
11. Surveyed Experts Indicate That Byetta LAR and Victoza Have Advantages Over Actos in the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 2016 , ... This CAST literature review and report looks at problems caused ... the economic effects in countries that are major global commodity exporters and importers, which ... risk of low level presence (LLP) puts large volumes of trade worth billions of ...
(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...
(Date:12/8/2016)... 2016 Savannah River Remediation LLC group ... NewTechBio,s NT-MAX Lake & Pond Sludge and ... in conjunction with Hexa Armor/ Rhombo cover manufactured ... Pollutant Discharge Elimination System requirements. The ... history of elevated pH levels, above 8.5, especially ...
(Date:12/8/2016)... 2016  Partnering to fuel Philadelphia,s ... of Southeastern Pennsylvania (" Ben ... of Independence Blue Cross; and Safeguard Scientifics ("Safeguard") (NYSE: ... a $6 million funding initiative over a four year ... Responding to a burgeoning economic vitality in digital health, ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
(Date:12/5/2016)... , Dec. 5, 2016  The Office ... today published "Can CT Scans Enhance or Replace ... the potential of supporting or replacing forensic autopsies ... CT scan. In response to recommendations ... is exploring using CT scans as a potential ...
(Date:11/29/2016)... BioDirection, a privately held medical device company developing novel ... concussion and other traumatic brain injury (TBI), announced today ... the U.S. Food and Drug Administration (FDA) to review ... meeting company representatives reviewed plans for clinical development of ... a planned pilot trial. "We are ...
Breaking Biology News(10 mins):